FORTE BIOSCIENCES INC (FBRX) — insider trading
Health Care · NASDAQ
FORTE BIOSCIENCES INC (FBRX) has 20 reported SEC Form 4 insider transactions in our data (latest 2026-07-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | Wagner Paul A. | Director, Officer (SEE REMARKS) | Option exercise / conversion (derivative) | 1,250 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Wagner Paul A. | Director, Officer (SEE REMARKS) | Shares withheld for taxes / exercise cost | 98 | $21.32 | $2.1K | Form 4 |
| 2026-07-01 | Wagner Paul A. | Director, Officer (SEE REMARKS) | Option exercise / conversion | 1,250 | — | — | Form 4 |
| 2026-07-01 | Riley Antony A | Officer (CHIEF FINANCIAL OFFICER) | Option exercise / conversion (derivative) | 375 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Riley Antony A | Officer (CHIEF FINANCIAL OFFICER) | Shares withheld for taxes / exercise cost | 134 | $21.32 | $2.9K | Form 4 |
| 2026-07-01 | Riley Antony A | Officer (CHIEF FINANCIAL OFFICER) | Option exercise / conversion | 375 | — | — | Form 4 |
| 2026-06-16 | Wagner Paul A. | Director, Officer (SEE REMARKS) | Grant / award / vesting (derivative) | 500,000 | $0.00 | $0 | Form 4 |
| 2026-06-16 | Riley Antony A | Officer (CHIEF FINANCIAL OFFICER) | Grant / award / vesting (derivative) | 22,000 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Kornfeld Steven | Director | Grant / award / vesting (derivative) | 18,353 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Brun Scott C. | Director | Grant / award / vesting (derivative) | 18,353 | $0.00 | $0 | Form 4 |
| 2026-05-29 | GRYSKA DAVID W | Director | Grant / award / vesting (derivative) | 18,353 | $0.00 | $0 | Form 4 |
| 2026-05-29 | VINCENT RICHARD G | Director | Grant / award / vesting (derivative) | 18,353 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Kapoor Shivpreet Singh | Director | Grant / award / vesting (derivative) | 18,353 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Doberstein Stephen K | Director | Grant / award / vesting (derivative) | 18,353 | $0.00 | $0 | Form 4 |
| 2026-04-01 | Wagner Paul A. | Director, Officer (SEE REMARKS) | Option exercise / conversion (derivative) | 1,250 | $0.00 | $0 | Form 4 |
| 2026-04-01 | Wagner Paul A. | Director, Officer (SEE REMARKS) | Shares withheld for taxes / exercise cost | 98 | $24.86 | $2.4K | Form 4 |
| 2026-04-01 | Wagner Paul A. | Director, Officer (SEE REMARKS) | Option exercise / conversion | 1,250 | — | — | Form 4 |
| 2026-04-01 | Riley Antony A | Officer (CHIEF FINANCIAL OFFICER) | Option exercise / conversion (derivative) | 375 | $0.00 | $0 | Form 4 |
| 2026-04-01 | Riley Antony A | Officer (CHIEF FINANCIAL OFFICER) | Shares withheld for taxes / exercise cost | 134 | $24.86 | $3.3K | Form 4 |
| 2026-04-01 | Riley Antony A | Officer (CHIEF FINANCIAL OFFICER) | Option exercise / conversion | 375 | — | — | Form 4 |
Ask the chat about FBRX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: FORTE BIOSCIENCES INC (FBRX).
Last updated 2026-07-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.